Skip to main content
. 2011 Dec 27;2:74. doi: 10.3389/fimmu.2011.00074

Figure 1.

Figure 1

Cumulative incidence for aGvHD following BMT based on HLA-G recipient genotype (grade 0, I versus II, III, IV).